Inovio reports data from Phase 1/2 trial on INO-3107

INOVIO (INO) announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously observed in a Phase 1/2 trial of RRP patients. In that prior trial, patients experienced a reduction in surgeries needed to control their RRP caused by HPV-6 and HPV-11. In the recent immunology study, INO-3107 induced the expansion of both existing and new clonal T cells that travel from the blood to the papilloma and airway tissues. The new clonal T cells accounted for the majority of T cells observed in patient papilloma or airway tissue who showed either a complete or partial response to treatment with INO-3107. These new data build upon previously reported evidence that INO-3107 elicits an antigen-specific immune response targeting HPV-6 and HPV-11, to help eliminate or control RRP by reducing the need for surgery. Summary of Immunology Data: The new immunology data is to be presented at the 36th International Papillomavirus Conference. It builds on data presented at the American Association for Cancer Research (AACR) Special Conference on October 19. Collectively, these immunology data provide further support of INO-3107’s ability to induce antigen-specific T cell responses against HPV-6 and HPV-11 and drive recruitment of T cells into papilloma and airway tissues of RRP patients, which could potentially slow or eliminate papilloma regrowth.